Citation Report
List of articles citing

Erectile dysfunction and hypertension

DOI: 10.1038/sj.ijir.3901527
International Journal of Impotence Research, 2007, 19, 296-3

Source: https://exaly.com/paper-pdf/41395618/citation-report.pdf
Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
72	Cardiac disease and sexuality: implications for research and practice. *Nursing Clinics of North America*, **2007**, 42, 593-603; vii	1.6	21
71	Erectile dysfunction in men with congenital heart disease. *American Journal of Cardiology*, **2008**, 102, 1728-30	3	24
70	NADPH oxidase activation: a mechanism of hypertension-associated erectile dysfunction. *Journal of Sexual Medicine*, **2008**, 5, 544-51	1.1	68
69	Association among metabolic syndrome, testosterone level and severity of erectile dysfunction. *Kaohsiung Journal of Medical Sciences*, **2008**, 24, 240-7	2.4	15
68	The engineering analysis of bioheat equation and penile hemodynamic relationships in the diagnosis of erectile dysfunction: part II-model optimization using the ANOVA and Taguchi method. *International Journal of Impotence Research*, **2008**, 20, 285-94	2.3	3
67	The mineralocorticoid receptor in endothelial physiology and disease: novel concepts in the understanding of erectile dysfunction. *Current Pharmaceutical Design*, **2008**, 14, 3749-57	3.3	17
66	Erectile dysfunction, cardiovascular diseases and depression: interaction of therapy. *Expert Opinion on Pharmacotherapy*, **2009**, 10, 2107-17	4	6
65	Erectile dysfunction and heart failure: the role of phosphodiesterase type 5 inhibitors. *International Journal of Impotence Research*, **2009**, 21, 149-57	2.3	12
64	Blood pressure lowering effects of a new long-acting inhibitor of phosphodiesterase 5 in patients with mild to moderate hypertension. *Hypertension*, **2009**, 53, 1091-7	8.5	19
63	Pulse pressure, an index of arterial stiffness, is associated with androgen deficiency and impaired penile blood flow in men with ED. *Journal of Sexual Medicine*, **2009**, 6, 285-93	1.1	54
62	Clinical and metabolic evaluation of subjects with erectile dysfunction: a review with a proposal flowchart. *Journal of Developmental and Physical Disabilities*, **2009**, 32, 198-211		37
61	Aplicaci□n pr□ctica de la evaluaci□n de la funci□n er□til en el paciente hipertenso. *Hipertension Y Riesgo Vascular*, **2009**, 26, 229-236	0.5	
60	[Etiology and management of erectile dysfunction in patients with diabetes mellitus]. *Progres En Urologie*, **2009**, 19, 364-71	0.9	7
59	Cardiovascular aspects of sexual medicine. *Journal of Sexual Medicine*, **2010**, 7, 1608-26	1.1	80
58	Development of an immunoassay for rapid screening of vardenafil and its potential analogues in herbal products based on a group specific monoclonal antibody. *Analytica Chimica Acta*, **2010**, 658, 197-203	4.6	24
57	Evaluation of erectile dysfunction and associated cardiovascular risk using structured questionnaires in Chinese type 2 diabetic men. *Journal of Developmental and Physical Disabilities*, **2010**, 33, 853-60		19
56	Antihypertensive drugs and erectile dysfunction as seen in spontaneous reports, with focus on angiotensin II type 1 receptor blockers. *Drug, Healthcare and Patient Safety*, **2010**, 2, 21-5	1.6	7

55	A multicenter, double-blind, placebo-controlled trial to assess the efficacy of sildenafil citrate in men with unrecognized erectile dysfunction. *Urology*, **2010**, 76, 373-9	1.6	9
54	Erectile dysfunction in patients with psoriasis: increased prevalence, an unmet need, and a chance to intervene. *British Journal of Dermatology*, **2011**, 164, 103-9	4	38
53	Impact of hypertension, aging, and antihypertensive treatment on the morphology of the pudendal artery. *Journal of Sexual Medicine*, **2011**, 8, 1027-38	1.1	22
52	Relationship between erectile dysfunction and silent myocardial ischemia in type 2 diabetic patients with no known macrovascular complications. *Journal of Sexual Medicine*, **2011**, 8, 2606-16	1.1	23
51	Circulating matrix metalloproteinases and their endogenous inhibitors in patients with erectile dysfunction. *International Journal of Impotence Research*, **2012**, 24, 38-43	2.3	8
50	Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. *Circulation*, **2012**, 125, 1058-72	16.7	202
49	Erectile dysfunction and hypertension: impact on cardiovascular risk and treatment. *International Journal of Hypertension*, **2012**, 2012, 627278	2.4	44
48	The Princeton III Consensus recommendations for the management of erectile dysfunction and cardiovascular disease. *Mayo Clinic Proceedings*, **2012**, 87, 766-78	6.4	297
47	Selectivity of avanafil, a PDE5 inhibitor for the treatment of erectile dysfunction: implications for clinical safety and improved tolerability. *Journal of Sexual Medicine*, **2012**, 9, 2122-9	1.1	55
46	VEGF genetic polymorphisms affect the responsiveness to sildenafil in clinical and postoperative erectile dysfunction. *Pharmacogenomics Journal*, **2013**, 13, 437-42	3.5	14
45	Endothelial nitric oxide synthase genotypes and haplotypes modify the responses to sildenafil in patients with erectile dysfunction. *Pharmacogenomics Journal*, **2013**, 13, 189-96	3.5	28
44	Obesity and Sexual Dysfunction in Men. **2013**, 141-161		2
43	The relationship of retinal vessel caliber with erectile dysfunction in patients with type 2 diabetes. **2013**, 54, 7234-9		9
42	Sildenafil and analogous phosphodiesterase type 5 (PDE-5) inhibitors in herbal food supplements sampled on the Dutch market. *Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment*, **2013**, 30, 2027-34	3.2	19
41	nNOS polymorphisms are associated with responsiveness to sildenafil in clinical and postoperative erectile dysfunction. *Pharmacogenomics*, **2014**, 15, 775-84	2.6	10
40	Pharmacogenetics of erectile dysfunction: navigating into uncharted waters. *Pharmacogenomics*, **2014**, 15, 1519-38	2.6	20
39	Relationship between Arginase 1 and Arginase 2 levels and genetic polymorphisms with erectile dysfunction. *Nitric Oxide - Biology and Chemistry*, **2015**, 51, 36-42	5	19
38	Phosphodiesterase 5 Inhibitor Use in Men With Hypertrophic Cardiomyopathy. *American Journal of Cardiology*, **2015**, 116, 618-21	3	3

37	Misconceptions and facts about treating hypertension. *American Journal of Medicine*, **2015**, 128, 450-5	2.4	5
36	Erectile Dysfunction in Hypertension and Cardiovascular Disease. **2015**,		2
35	Hydrochlorothiazide Potentiates Contractile Activity of Mouse Cavernosal Smooth Muscle. *Sexual Medicine*, **2016**, 4, e113-23	2.7	2
34	Antihypertensive Drugs and Male Sexual Dysfunction: A Review of Adult Hypertension Guideline Recommendations. *Journal of Cardiovascular Pharmacology and Therapeutics*, **2016**, 21, 233-44	2.6	24
33	The correlation between high sensitivity C-reactive protein and erectile dysfunction patients with hypertension treated with vardenafil. *International Journal of Impotence Research*, **2017**, 29, 82-85	2.3	3
32	Clinical, cultural and psychosocial impediments to self reporting of erectile dysfunction by men in Edo state, Nigeria. *African Journal of Urology*, **2017**, 23, 160-165	1	1
31	Prévalence et facteurs de risque de la dysfonction érectile chez les insuffisants rénaux chroniques. *African Journal of Urology*, **2017**, 23, 331-337	1	1
30	Hypertension might be a risk factor for erectile dysfunction: a meta-analysis. *Andrologia*, **2017**, 49, e12644	2.4	14
29	Penile Erection Induced by Scoparone from Artemisia capillaris through the Nitric Oxide-Cyclic Guanosine Monophosphate Signaling Pathway. *World Journal of Men?s Health*, **2017**, 35, 196-204	6.8	10
28	Drug-related problems in patients with erectile dysfunctions and multiple comorbidities. *Therapeutics and Clinical Risk Management*, **2017**, 13, 407-419	2.9	3
27	Influence of arginase polymorphisms and arginase levels/activity on the response to erectile dysfunction therapy with sildenafil. *Pharmacogenomics Journal*, **2018**, 18, 238-244	3.5	8
26	Effect of phosphodiesterase 5 inhibitors on blood pressure. *The Cochrane Library*, **2019**,	5.2	78
25	Blood pressure, antihypertensive medication use, and risk of erectile dysfunction in men with type I diabetes. *Journal of Hypertension*, **2019**, 37, 1070-1076	1.9	5
24	Angiotensin Receptor Blockers for Erectile Dysfunction in Hypertensive Men: A Brief Meta-Analysis of Randomized Control Trials. *American Journal of Men's Health*, **2019**, 13, 1557988319892735	2.2	4
23	Blood Pressure, Sexual Activity, and Erectile Function in Hypertensive Men: Baseline Findings from the Systolic Blood Pressure Intervention Trial (SPRINT). *Journal of Sexual Medicine*, **2019**, 16, 235-247	1.1	13
22	Review of the current information on erectile dysfunction in hypertensive males with 40 years of age or older. *Porto Biomedical Journal*, **2020**, 5, e107	1.1	1
21	Obesity and sexual dysfunction in men. **2020**, 105-118		0
20	Effects of chronic type 5 phosphodiesterase inhibition on penile microvascular reactivity in hypertensive patients with erectile dysfunction: a randomized crossover placebo-controlled trial. *Journal of Human Hypertension*, **2021**, 35, 360-370	2.6	1

19	Hypertension and Erectile Dysfunction: Breaking Down the Challenges. *American Journal of Hypertension*, **2021**, 34, 134-142	2.3	6
18	Management pathways for erectile dysfunction in primary care. *Practice Nursing*, **2021**, 32, 16-20	0.1	
17	Risk characterisation of constituents present in jamu to promote its safe use. *Critical Reviews in Toxicology*, **2021**, 51, 183-191	5.7	1
16	Management pathways for erectile dysfunction in primary care. *Journal of Prescribing Practice*, **2021**, 3, 112-118	0.1	
15	PDE-5 inhibitors in selected herbal supplements from the Ghanaian market for better erectile function as tested by a bioassay. *Toxicology in Vitro*, **2021**, 73, 105130	3.6	1
14	The Role and Efficacy of Coenzyme Q10 in the Management of Erectile Dysfunction in a Hypertensive Male: An Interventional Study. *Cureus*, **2021**, 13, e17937	1.2	
13	Effects of metformin on endothelial health and erectile dysfunction. *Translational Andrology and Urology*, **2017**, 6, 556-565	2.3	13
12	Russian clinical guidelines Coronary artery bypass grafting in patients with ischemic heart disease: rehabilitation and secondary prevention. *Cardiosomatics*, **2016**, 7, 5-71	0.4	35
11	Erectile dysfunction in patients with liver disease related to chronic hepatitis B. *Clinical and Molecular Hepatology*, **2015**, 21, 352-7	6.9	11
10	Erectile Dysfunction. **2009**, 519-526		
9	Role of Oxidative Stress in ED: Unraveling the Molecular Mechanism. **2012**, 617-643		
8	Basic Principles of the Princeton Recommendations. **2015**, 213-229		
7	Hypertension and reproductive dysfunction: a possible role of inflammation and inflammation-associated lymphangiogenesis in gonads. *Clinical Science*, **2020**, 134, 3237-3257	6.5	2
6	Comparison of the Prevalence of Erectile Dysfunction Between Hypertensive and Normotensive Participants: A Case-Control Study. *Cureus*, **2020**, 12, e12061	1.2	
5	Analysis of integrated clinical safety data of tadalafil in patients receiving concomitant antihypertensive medications.. *Journal of Clinical Hypertension*, **2022**,	2.3	3
4	Identification of phosphodiesterase type-5 (PDE-5) inhibitors in herbal supplements using a tiered approach and associated consumer risk.. *Food Additives and Contaminants - Part A Chemistry, Analysis, Control, Exposure and Risk Assessment*, **2022**, 1-12	3.2	0
3	Wearable E-Textile and CNT Sensor Wireless Measurement System for Real-Time Penile Erection Monitoring.. *Sensors*, **2021**, 22,	3.8	0
2	Natural toxicants in plant-based foods, including herbs and spices and herbal food supplements, and accompanying risks. **2023**, 2-25		0

1	The association of genetically proxied sildenafil with fertility, sexual activity, and wellbeing: a Mendelian randomisation study.	0